JP2002506044A - Ｇｄｆ−８およびｂｍｐ−１１をモジュレーションするためのフォリスタチンの使用 - Google Patents
Ｇｄｆ−８およびｂｍｐ−１１をモジュレーションするためのフォリスタチンの使用Info
- Publication number
- JP2002506044A JP2002506044A JP2000535362A JP2000535362A JP2002506044A JP 2002506044 A JP2002506044 A JP 2002506044A JP 2000535362 A JP2000535362 A JP 2000535362A JP 2000535362 A JP2000535362 A JP 2000535362A JP 2002506044 A JP2002506044 A JP 2002506044A
- Authority
- JP
- Japan
- Prior art keywords
- follistatin
- bmp
- gdf
- protein
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108010014612 Follistatin Proteins 0.000 title claims abstract description 78
- 102000016970 Follistatin Human genes 0.000 title claims abstract description 78
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 title claims abstract description 45
- 101710194452 Growth/differentiation factor 11 Proteins 0.000 title claims abstract description 45
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 title abstract 3
- 108010056852 Myostatin Proteins 0.000 title abstract 3
- 238000000034 method Methods 0.000 claims abstract description 31
- 230000000694 effects Effects 0.000 claims abstract description 25
- 210000003205 muscle Anatomy 0.000 claims abstract description 13
- 210000005036 nerve Anatomy 0.000 claims abstract description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 230000004069 differentiation Effects 0.000 claims description 9
- 230000012010 growth Effects 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 102000001690 Factor VIII Human genes 0.000 claims description 4
- 108010054218 Factor VIII Proteins 0.000 claims description 4
- 230000000903 blocking effect Effects 0.000 claims description 2
- 230000002900 effect on cell Effects 0.000 claims description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 abstract description 3
- 208000025966 Neurological disease Diseases 0.000 abstract description 2
- 208000029578 Muscle disease Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 27
- 230000027455 binding Effects 0.000 description 18
- 239000012634 fragment Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 239000013615 primer Substances 0.000 description 7
- 239000003446 ligand Substances 0.000 description 6
- 108010059616 Activins Proteins 0.000 description 5
- 108700024394 Exon Proteins 0.000 description 5
- 102100026818 Inhibin beta E chain Human genes 0.000 description 5
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 5
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 5
- 239000000488 activin Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 210000003716 mesoderm Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 208000005264 motor neuron disease Diseases 0.000 description 3
- 201000006938 muscular dystrophy Diseases 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 229920002971 Heparan sulfate Polymers 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 101000931668 Homo sapiens Follistatin Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000269370 Xenopus <genus> Species 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 201000010901 lateral sclerosis Diseases 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000018918 Activin Receptors Human genes 0.000 description 1
- 108010052946 Activin Receptors Proteins 0.000 description 1
- 102000002572 Alpha-Globulins Human genes 0.000 description 1
- 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 description 1
- 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 description 1
- 102100028728 Bone morphogenetic protein 1 Human genes 0.000 description 1
- 108090000654 Bone morphogenetic protein 1 Proteins 0.000 description 1
- 102100033779 Collagen alpha-4(IV) chain Human genes 0.000 description 1
- 208000037141 Congenital muscular dystrophy, Fukuyama type Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 208000001441 Familial Periodic Paralyses Diseases 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 201000006813 Fukuyama congenital muscular dystrophy Diseases 0.000 description 1
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
- 101000710870 Homo sapiens Collagen alpha-4(IV) chain Proteins 0.000 description 1
- 101000835998 Homo sapiens SRA stem-loop-interacting RNA-binding protein, mitochondrial Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102100039352 Immunoglobulin heavy constant mu Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028424 Myasthenic syndrome Diseases 0.000 description 1
- 206010028629 Myoglobinuria Diseases 0.000 description 1
- 208000010316 Myotonia congenita Diseases 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 102100025491 SRA stem-loop-interacting RNA-binding protein, mitochondrial Human genes 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108090000054 Syndecan-2 Proteins 0.000 description 1
- 206010042928 Syringomyelia Diseases 0.000 description 1
- 102000007453 TGF-beta Superfamily Proteins Human genes 0.000 description 1
- 108010085004 TGF-beta Superfamily Proteins Proteins 0.000 description 1
- 108091005735 TGF-beta receptors Proteins 0.000 description 1
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 1
- 201000006793 Walker-Warburg syndrome Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000625 blastula Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 201000011474 congenital myopathy Diseases 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 206010016208 familial periodic paralysis Diseases 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 102000050536 human FST Human genes 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 208000025855 muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4 Diseases 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 206010030875 ophthalmoplegia Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/037,118 US6004937A (en) | 1998-03-09 | 1998-03-09 | Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11] |
| US09/037,118 | 1998-03-09 | ||
| PCT/US1999/004003 WO1999045949A2 (en) | 1998-03-09 | 1999-02-24 | Use of follistatin to modulate gdf-8 and bmp-11 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009222855A Division JP2010043099A (ja) | 1998-03-09 | 2009-09-28 | Ｇｄｆ−８およびｂｍｐ−１１をモジュレーションするためのフォリスタチンの使用 |
| JP2010061242A Division JP2010195794A (ja) | 1998-03-09 | 2010-03-17 | Ｇｄｆ−８およびｂｍｐ−１１をモジュレーションするためのフォリスタチンの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002506044A true JP2002506044A (ja) | 2002-02-26 |
| JP2002506044A5 JP2002506044A5 (https=) | 2006-07-06 |
Family
ID=21892528
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000535362A Withdrawn JP2002506044A (ja) | 1998-03-09 | 1999-02-24 | Ｇｄｆ−８およびｂｍｐ−１１をモジュレーションするためのフォリスタチンの使用 |
| JP2009222855A Pending JP2010043099A (ja) | 1998-03-09 | 2009-09-28 | Ｇｄｆ−８およびｂｍｐ−１１をモジュレーションするためのフォリスタチンの使用 |
| JP2010061242A Pending JP2010195794A (ja) | 1998-03-09 | 2010-03-17 | Ｇｄｆ−８およびｂｍｐ−１１をモジュレーションするためのフォリスタチンの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009222855A Pending JP2010043099A (ja) | 1998-03-09 | 2009-09-28 | Ｇｄｆ−８およびｂｍｐ−１１をモジュレーションするためのフォリスタチンの使用 |
| JP2010061242A Pending JP2010195794A (ja) | 1998-03-09 | 2010-03-17 | Ｇｄｆ−８およびｂｍｐ−１１をモジュレーションするためのフォリスタチンの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6004937A (https=) |
| EP (3) | EP1444985A3 (https=) |
| JP (3) | JP2002506044A (https=) |
| AT (1) | ATE256475T1 (https=) |
| AU (1) | AU759838B2 (https=) |
| CA (1) | CA2322716C (https=) |
| DE (1) | DE69913665T2 (https=) |
| DK (1) | DK1061940T3 (https=) |
| ES (1) | ES2212533T3 (https=) |
| PT (1) | PT1061940E (https=) |
| WO (1) | WO1999045949A2 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005323584A (ja) * | 2004-04-15 | 2005-11-24 | Techno Network Shikoku Co Ltd | フォリスタチン変異体ポリペプチド |
| JP2010043099A (ja) * | 1998-03-09 | 2010-02-25 | Genetics Inst Llc | Ｇｄｆ−８およびｂｍｐ−１１をモジュレーションするためのフォリスタチンの使用 |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6150328A (en) | 1986-07-01 | 2000-11-21 | Genetics Institute, Inc. | BMP products |
| WO1993009229A1 (en) | 1991-11-04 | 1993-05-13 | Genetics Institute, Inc. | Recombinant bone morphogenetic protein heterodimers, compositions and methods of use |
| US7393682B1 (en) | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
| US7566768B1 (en) | 1995-10-26 | 2009-07-28 | The Johns Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
| WO1994026892A1 (en) * | 1993-05-12 | 1994-11-24 | Genetics Institute, Inc. | Bmp-11 compositions |
| US6291206B1 (en) | 1993-09-17 | 2001-09-18 | Genetics Institute, Inc. | BMP receptor proteins |
| AU689184B2 (en) | 1993-12-07 | 1998-03-26 | Genetics Institute, Llc | BMP-12, BMP-13 and tendon-inducing compositions thereof |
| US6008434A (en) | 1994-07-08 | 1999-12-28 | Johns Hopkins University School Of Medicine | Growth differentiation factor-11 transgenic mice |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| US6891082B2 (en) * | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| US6696260B1 (en) * | 1997-08-01 | 2004-02-24 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (GDF) binding proteins |
| US6727224B1 (en) | 1999-02-01 | 2004-04-27 | Genetics Institute, Llc. | Methods and compositions for healing and repair of articular cartilage |
| WO2001009368A1 (en) * | 1999-07-30 | 2001-02-08 | The General Hospital Corporation | Follistatin antagonists |
| DK1223990T3 (da) | 1999-10-15 | 2004-11-29 | Inst Genetics Llc | Formuleringer af hyaluronsyre til tilförsel af osteogene proteiner |
| TW200526779A (en) * | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
| EP1790726B1 (en) * | 2001-02-08 | 2013-07-03 | Wyeth LLC | Modified and stabilized GDF propeptides and uses thereof |
| KR100420798B1 (ko) * | 2001-02-10 | 2004-03-02 | (주)알에이싸이언스 | 펩타이드 벡터 |
| US7226587B2 (en) | 2001-06-01 | 2007-06-05 | Wyeth | Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins |
| TWI267378B (en) | 2001-06-08 | 2006-12-01 | Wyeth Corp | Calcium phosphate delivery vehicles for osteoinductive proteins |
| US20030103959A1 (en) * | 2001-06-22 | 2003-06-05 | Hughes Paul E. | Methods of providing neuroprotection and/or neurorestoration via the neural activin type IIB receptor |
| US7320789B2 (en) * | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| US6798160B2 (en) * | 2001-11-02 | 2004-09-28 | Honda Giken Kogyo Kabushiki Kaisha | Electric working machine |
| US20030144203A1 (en) * | 2001-12-19 | 2003-07-31 | Voyager Pharmaceutical Corporation | Methods for slowing senescence and treating and preventing diseases associated with senescence |
| GB2385052A (en) * | 2002-02-05 | 2003-08-13 | Leuven K U Res & Dev | Treatment of spondyloarthropathies |
| EP1572909A4 (en) * | 2002-02-21 | 2007-06-06 | Wyeth Corp | PROTEIN CONTAINING A DOMAINE OF FOLLISTATIN |
| BR0307871A (pt) | 2002-02-21 | 2005-04-12 | Wyeth Corp | Proteìnas contendo domìnio de folistatina |
| MXPA05002968A (es) * | 2002-09-16 | 2005-09-08 | Univ Johns Hopkins | Activacion de miostatina por metaloproteasa, y metodos de modular la actividad de miostatina. |
| AR047392A1 (es) | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
| US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| US20050192225A1 (en) * | 2002-12-18 | 2005-09-01 | Bowen Richard L. | Methods for treating Parkinson's disease |
| RU2322261C2 (ru) * | 2003-06-02 | 2008-04-20 | Уайт | Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний |
| JP5392981B2 (ja) | 2003-09-12 | 2014-01-22 | ワイス・エルエルシー | 骨形成蛋白の送達のための注入可能なリン酸カルシウム固体ロッドおよびペースト |
| EP1699820A2 (en) * | 2003-12-31 | 2006-09-13 | Schering-Plough Ltd. | Neutralizing epitope-based growth enhancing vaccine |
| AU2005272646A1 (en) * | 2004-08-12 | 2006-02-23 | Wyeth | Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors |
| CA2594276A1 (en) | 2004-12-30 | 2006-07-13 | Schering-Plough Ltd. | Neutralizing epitope-based growth enhancing vaccine |
| WO2006081379A1 (en) * | 2005-01-26 | 2006-08-03 | Wyeth | Use of sfrps as markers of bmp activity |
| NZ538097A (en) * | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
| JP2008537777A (ja) * | 2005-03-23 | 2008-09-25 | ワイス | Ｇｄｆ−８調節剤に対する免疫応答の検出 |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| TW201803890A (zh) | 2007-02-02 | 2018-02-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| US8236751B2 (en) * | 2007-03-07 | 2012-08-07 | The Johns Hopkins University | Methods of increasing muscle mass using follistatin-like related gene (FLRG) |
| CA2685540C (en) | 2007-08-03 | 2018-10-16 | Graham Michael Wynne | Drug combinations for the treatment of duchenne muscular dystrophy |
| GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
| CN102131822A (zh) | 2008-06-26 | 2011-07-20 | 阿塞勒隆制药公司 | 进行激活素-ActRIIa拮抗剂给药和监测受治疗患者的方法 |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| US9873739B2 (en) | 2012-08-01 | 2018-01-23 | Ikaika Therapeutics, Llc | Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (LTBP4) |
| EA202090632A1 (ru) | 2014-06-04 | 2020-07-31 | Акселерон Фарма Инк. | Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов |
| US10010498B2 (en) | 2014-06-04 | 2018-07-03 | Acceleron Pharma Inc. | Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins |
| EP3274457A4 (en) | 2015-03-26 | 2018-08-08 | Acceleron Pharma Inc. | Follistatin-related fusion proteins and uses thereof |
| WO2019046903A1 (en) * | 2017-09-08 | 2019-03-14 | Baker Heart and Diabetes Institute | THERAPEUTIC METHOD FOR INCREASING MUSCLE MASS IN A SUBJECT |
| WO2020132647A1 (en) | 2018-12-21 | 2020-06-25 | Northwestern University | Use of annexins in preventing and treating muscle membrane injury |
| WO2020139977A1 (en) | 2018-12-26 | 2020-07-02 | Northwestern University | Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5041538A (en) * | 1987-08-28 | 1991-08-20 | The Salk Institute For Biological Studies | Mammalian follistatin |
| US5171579A (en) * | 1991-10-11 | 1992-12-15 | Genetics Institute, Inc. | Formulations of blood clot-polymer matrix for delivery of osteogenic proteins |
| DK0690873T3 (da) * | 1993-03-19 | 2003-09-29 | Univ Johns Hopkins Med | Vækstdifferentieringsfaktor-8 |
| WO1994026892A1 (en) * | 1993-05-12 | 1994-11-24 | Genetics Institute, Inc. | Bmp-11 compositions |
| JPH09503673A (ja) * | 1993-10-14 | 1997-04-15 | プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ | ニューロン細胞の誘導および維持法 |
| US5545616A (en) * | 1994-09-22 | 1996-08-13 | Genentech, Inc. | Method for predicting and/or preventing preterm labor |
| US6281332B1 (en) * | 1994-12-02 | 2001-08-28 | The Johns Hopkins University School Of Medicine | Hedgehog-derived polypeptides |
| GB2306481A (en) * | 1995-10-21 | 1997-05-07 | Univ Manchester | Pharmaceutical comprising a stimulator of activin and/or inhibin |
| US6004937A (en) * | 1998-03-09 | 1999-12-21 | Genetics Institute, Inc. | Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11] |
-
1998
- 1998-03-09 US US09/037,118 patent/US6004937A/en not_active Expired - Lifetime
-
1999
- 1999-02-24 DK DK99908416T patent/DK1061940T3/da active
- 1999-02-24 PT PT99908416T patent/PT1061940E/pt unknown
- 1999-02-24 AU AU27854/99A patent/AU759838B2/en not_active Ceased
- 1999-02-24 EP EP03028901A patent/EP1444985A3/en not_active Withdrawn
- 1999-02-24 WO PCT/US1999/004003 patent/WO1999045949A2/en not_active Ceased
- 1999-02-24 ES ES99908416T patent/ES2212533T3/es not_active Expired - Lifetime
- 1999-02-24 EP EP99908416A patent/EP1061940B1/en not_active Expired - Lifetime
- 1999-02-24 EP EP10185247A patent/EP2347760A3/en not_active Withdrawn
- 1999-02-24 AT AT99908416T patent/ATE256475T1/de active
- 1999-02-24 DE DE69913665T patent/DE69913665T2/de not_active Expired - Lifetime
- 1999-02-24 CA CA2322716A patent/CA2322716C/en not_active Expired - Fee Related
- 1999-02-24 JP JP2000535362A patent/JP2002506044A/ja not_active Withdrawn
-
2009
- 2009-09-28 JP JP2009222855A patent/JP2010043099A/ja active Pending
-
2010
- 2010-03-17 JP JP2010061242A patent/JP2010195794A/ja active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010043099A (ja) * | 1998-03-09 | 2010-02-25 | Genetics Inst Llc | Ｇｄｆ−８およびｂｍｐ−１１をモジュレーションするためのフォリスタチンの使用 |
| JP2005323584A (ja) * | 2004-04-15 | 2005-11-24 | Techno Network Shikoku Co Ltd | フォリスタチン変異体ポリペプチド |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2785499A (en) | 1999-09-27 |
| DE69913665D1 (de) | 2004-01-29 |
| EP1444985A3 (en) | 2006-12-27 |
| CA2322716A1 (en) | 1999-09-16 |
| ATE256475T1 (de) | 2004-01-15 |
| EP1061940B1 (en) | 2003-12-17 |
| CA2322716C (en) | 2010-08-24 |
| EP1444985A2 (en) | 2004-08-11 |
| JP2010195794A (ja) | 2010-09-09 |
| DE69913665T2 (de) | 2004-09-30 |
| DK1061940T3 (da) | 2004-04-05 |
| ES2212533T3 (es) | 2004-07-16 |
| AU759838B2 (en) | 2003-05-01 |
| WO1999045949A2 (en) | 1999-09-16 |
| PT1061940E (pt) | 2004-03-31 |
| US6004937A (en) | 1999-12-21 |
| JP2010043099A (ja) | 2010-02-25 |
| WO1999045949A3 (en) | 1999-11-18 |
| EP2347760A2 (en) | 2011-07-27 |
| EP1061940A2 (en) | 2000-12-27 |
| EP2347760A3 (en) | 2012-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002506044A (ja) | Ｇｄｆ−８およびｂｍｐ−１１をモジュレーションするためのフォリスタチンの使用 | |
| CN1159827A (zh) | 用作生长因子抑制物的FLT-4(类fms酪氨酸激酶)，FLT-15及其变异体 | |
| JP2002505851A (ja) | 骨形態形成タンパク（ｂｍｐ）−１７およびｂｍｐ−１８の組成物 | |
| JP2003532742A (ja) | 神経損傷の修復 | |
| JP2001512667A (ja) | ヒトオーファンレセプターｎｔｒ−１ | |
| JP2001511010A (ja) | ヒトｓｄｆ−５蛋白および組成物 | |
| JP2002511762A (ja) | ネズミおよびヒトのサーベラス様蛋白およびそれらを含有する組成物 | |
| JP2009142287A (ja) | フラズルドヌクレオチド配列、発現生成物、組成物および用途 | |
| JP2013514811A (ja) | 免疫原性が抑制されたｂｍｐ−７変異体 | |
| AU2003231603B2 (en) | Use of follistatin to modulate GDF-8 and BMP-11 | |
| HK1068258A (en) | Use of follistatin for the manufacture of a medicament for the treatment of a non-degenerative nervous system disorder | |
| HK1159996A (en) | Use of follistatin for the manufacture of a medicament for the treatment of a non-degenerative nervous system disorder | |
| AU753400C (en) | Orphan receptors | |
| WO2019246013A1 (en) | Peptides to enhance bone growth, repair and cell function | |
| MXPA00008771A (es) | Uso de folistatina para modular el factor de crecimiento y diferenciacion 8 [gdf-8]y la proteina morfogenetica de hueso 11 [bmp-11] | |
| AU764484B2 (en) | Orphan cytokine receptor | |
| JP2001519182A (ja) | 新規ｎｐｙファミリーメンバー | |
| AU4586402A (en) | Frazzled nucleotide sequences expression products compositions and uses | |
| MXPA00000242A (en) | Murine and human cerberus-like proteins and compositions comprising them | |
| JP2001352988A (ja) | ナトリウムチャンネルｓｃｎ３ａ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060222 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060518 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090428 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090715 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090723 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090826 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090902 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090928 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091117 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100317 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20100324 |